Find Clinical Trial

Home » Find Clinical Trials » Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

← Back

Study Phase	Phase 1-2

Therapeutic Area	Cancers

Indication	Cholangiocarcinoma

Sponsor	Institut de Recherches Internationales Servier

Active substance/ Medical device	Cisplatin, Durvalumab, Gemcitabine, Ivosidenib

Active Substance Code	S095031

Protocol Code	S095031-210

Eu CT	2024-514261-19-00

NCT Code	NCT06501625

Documents and links

Results are not yet available.

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.